Error message
Notice: Undefined index: content in _drupal_default_html_head() (line 345 of /var/www/vhosts/rovi.es/httpdocs/includes/common.inc).
|
Date |
Title |
Description |
PDF |
|
06 May 2026 |
On P&L |
The Company releases the press release related to the first three months of 2026 financial results.
|
Download |
|
06 May 2026 |
On P&L |
The Company releases the first three months of 2026 financial results presentation.
|
Download |
|
25 Feb 2026 |
On P&L |
The Company releases the press release related to the full year 2025 financial results.
|
Download |
|
25 Feb 2026 |
On P&L |
The Company releases the full year 2025 financial results presentation.
|
Download |
|
25 Feb 2026 |
About Corporate Governance |
The Company informs about the agreements adopted by the Board of Directors.
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
15 Feb 2022 |
On business and financial situation |
ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
|
Download |
|
14 Feb 2022 |
Share buy-back , stabilisation and treasury stock programme |
Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022
|
Download |
|
07 Feb 2022 |
Share buy-back , stabilisation and treasury stock programme |
Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022
|
Download |
|
31 Jan 2022 |
Share buy-back , stabilisation and treasury stock programme |
Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022
|
Download |
|
24 Jan 2022 |
Share buy-back , stabilisation and treasury stock programmes |
Share Buyback Program: transactions conducted between 17 January 2022 and 21 January 2022
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
06 Apr 2017 |
Contratos de liquidez y contrapartida |
Liquidity contract: transactions conducted in the first quarter of 2017
|
Download |
|
13 Mar 2017 |
Otros sobre negocio y situación financiera |
The Company releases the presentation related to its biosimilar of Enoxaparin
|
Download |
|
07 Mar 2017 |
Otros sobre negocio y situación financiera |
ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome
|
Download |
|
16 Feb 2017 |
Otros sobre Gobierno Corporativo |
The Company informs about the agreements adopted by the Board of Directors
|
Download |
|
16 Feb 2017 |
Informe anual de remuneraciones de los consejeros |
ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors
|
Download |
Pages
